Hormonal
Higher circulating levels of specific trans fatty acids (t-16:1n9 and t-18:1) are positively associated with an increased risk of incident type 2 diabetes in older adults, but this association is largely explained by their correlation with de novo lipogenesis (DNL) markers rather than a direct causal effect of the trans fats themselves.
Focus on overall dietary quality rather than fixating solely on trans fats. This study suggests that high levels of certain circulating fatty acids, which are linked to how your body produces its own fats (de novo lipogenesis), are associated with higher diabetes risk. Since dietary self-reports didn't show a clear link, prioritizing whole foods, fiber, and healthy fats (like those in fish and nuts) is likely more effective for diabetes prevention than just avoiding processed foods with trans fats.
In biomarker analyses... both t-16:1n9... and t-18:1... levels were associated with higher incident DM after adjustment for de novo lipogenesis fatty acids... These findings highlight the need for further observational, interventional, and experimental studies of the effects TFA on DM.
Why this rating
Large prospective cohort (Cardiovascular Health Study), long follow-up (up to 2010), objective biomarker measurement, but observational design limits causal inference.
Source
Circulating and Dietary <i>Trans</i> Fatty Acids and Incident Type 2 Diabetes in Older Adults: The Cardiovascular Health Study
Qianyi Wang et al. · Diabetes Care · 2015
DOI 10.2337/dc14-2101
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →